AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Nextech3D.AI Corporation
Video analysis: NTAR.CN
All videosNo video analysis for this stock yet. Request one from our team.
News: NTAR.CN
Traders shorten odds on October debut for Anthropic
Betting markets now put a 62% probability on Anthropic listing its shares by the end of October, up 19 percentage points, as the artificial intelligence...
Citi upgrades Flutter after 13% share price slide
Citi has upgraded Flutter Entertainment PLC (LSE:FLTR, NYSE:FLUT) to 'neutral' following the gambling group's second-quarter results, arguing that a 13%...
JD Sports appoints former IKEA boss Peter Agnefjäll as chair
JD Sports Fashion PLC (LSE:JD., OTC:JDSPY) has appointed Peter Agnefjäll as chair of the board with effect from 1 September 2026. Agnefjäll succeeds Darren...
Nextech3D.ai reports increase in new customer contracts through first seven months of 2026
Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF, FRA:1SS) reported growth in new customer contracts and contracted value across its Eventdex, Map D and KraftyLab...
Nextech3D.ai advances ARway acquisition as valuations confirmed
Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF, FRA:1SS), an AI-first event technology and 3D modeling company, has received final fairness opinions supporting its...
GSK hits three-month high as vaccines help earnings top forecasts
GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quarter expectations across its main measures and...
Nasdaq 100 enters correction as sell-off deepens, while Coke and Sherwin-Williams lead Dow
1:00pm: Chip selloff continues Chris Beauchamp, chief market analyst at IG, said another round of selling in tech stocks is keeping pressure on global...
Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy
Replimune (NASDAQ: REPL) shares fell nearly 31% on Tuesday after US Food and Drug Administration (FDA) staff reviewers raised concerns over the...
Similar companies
-
LQWD Technologies Corp
LQWD.V
·
Toronto Stock Exchange Ventures
Compare
-
NamSys Inc.
CTZ.V
·
Toronto Stock Exchange Ventures
Compare
-
Edge Total Intelligence Inc.
CTRL.V
·
Toronto Stock Exchange Ventures
Compare
-
EarthLabs Inc.
SPOT.V
·
Toronto Stock Exchange Ventures
Compare
-
RESAAS Services Inc.
RSS.V
·
Toronto Stock Exchange Ventures
Compare
-
ProStar Holdings Inc.
MAPS.V
·
Toronto Stock Exchange Ventures
Compare